What was the overall valuation of the US proteomics market in 2024?

The overall market valuation was $10.5 Billion in 2024. Read More

What is the projected market valuation for the US proteomics market by 2035?

The projected valuation for 2035 is $25.0 Billion. Read More

What is the expected CAGR for the US proteomics market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 8.21%. Read More

Which application segments are expected to show significant growth in the US proteomics market?

The application segments include Drug Discovery, Clinical Diagnostics, Biomarker Discovery, and Personalized Medicine, with valuations ranging from $2.1 Billion to $7.0 Billion. Read More

What are the key product types in the US proteomics market?

Key product types include Instruments, Reagents, Bioinformatics Tools, and Services, with valuations between $2.1 Billion and $10.0 Billion. Read More

Which technologies are driving the US proteomics market?

Technologies such as Mass Spectrometry, Chromatography, Microarray, and Electrophoresis are driving the market, with valuations from $1.05 Billion to $10.0 Billion. Read More

Who are the leading players in the US proteomics market?

Key players include Thermo Fisher Scientific, Agilent Technologies, Waters Corporation, and Bruker Corporation. Read More

What end-use segments are contributing to the US proteomics market growth?

End-use segments include Research Institutions, Pharmaceutical Companies, Academic Institutions, and Clinical Laboratories, with valuations from $2.0 Billion to $8.5 Billion. Read More

How does the US proteomics market compare to other regions?

While specific regional comparisons are not provided, the US market is characterized by strong growth and significant investments from leading companies. Read More

What factors are likely to influence the growth of the US proteomics market in the coming years?

Factors such as advancements in technology, increased funding for research, and the rising demand for personalized medicine may influence market growth. Read More

US Proteomics Market

ID: MRFR/LS/11828-CR

100 Pages

Satyendra Maurya

Last Updated: April 02, 2026

US Proteomics Market Research Report: Size, Share, Trend Analysis By Equipment (Chromatography, Mass Spectroscopy, and Protein Microarray), By Services (Laboratory Services, Data Analysis & Services, and Others), By Applications (Drug Discovery and Clinical Diagnosis), And By Region (North America, Europe, Asia-Pacific, And the Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Pharmaceutical, BY Application (USD Billion) | |
  1. 4.1.1 Drug Discovery | |
  2. 4.1.2 Clinical Diagnostics | |
  3. 4.1.3 Biomarker Discovery | |
  4. 4.1.4 Personalized Medicine |
2. 4.2 Pharmaceutical, BY Product Type (USD Billion) | |
  1. 4.2.1 Instruments | |
  2. 4.2.2 Reagents | |
  3. 4.2.3 Bioinformatics Tools | |
  4. 4.2.4 Services |
3. 4.3 Pharmaceutical, BY Technology (USD Billion) | |
  1. 4.3.1 Mass Spectrometry | |
  2. 4.3.2 Chromatography | |
  3. 4.3.3 Microarray | |
  4. 4.3.4 Electrophoresis |
4. 4.4 Pharmaceutical, BY End Use (USD Billion) | |
  1. 4.4.1 Research Institutions | |
  2. 4.4.2 Pharmaceutical Companies | |
  3. 4.4.3 Academic Institutions | |
  4. 4.4.4 Clinical Laboratories 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Thermo Fisher Scientific (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Agilent Technologies (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Waters Corporation (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Bruker Corporation (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 PerkinElmer (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Merck KGaA (DE) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Bio-Rad Laboratories (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 F. Hoffmann-La Roche (CH) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Danaher Corporation (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 US MARKET ANALYSIS BY APPLICATION |
6. 6.3 US MARKET ANALYSIS BY PRODUCT TYPE |
7. 6.4 US MARKET ANALYSIS BY TECHNOLOGY |
8. 6.5 US MARKET ANALYSIS BY END USE |
9. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF PHARMACEUTICAL |
12. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL |
14. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL |
15. 6.12 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE) |
16. 6.13 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Billion) |
17. 6.14 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE) |
18. 6.15 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion) |
19. 6.16 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE) |
20. 6.17 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Billion) |
21. 6.18 PHARMACEUTICAL, BY END USE, 2024 (% SHARE) |
22. 6.19 PHARMACEUTICAL, BY END USE, 2024 TO 2035 (USD Billion) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY PRODUCT TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USE, 2025-2035 (USD Billion) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Application (USD Billion, 2025-2035)

Drug Discovery
Clinical Diagnostics
Biomarker Discovery
Personalized Medicine

Pharmaceutical By Product Type (USD Billion, 2025-2035)

Instruments
Reagents
Bioinformatics Tools
Services

Pharmaceutical By Technology (USD Billion, 2025-2035)

Mass Spectrometry
Chromatography
Microarray
Electrophoresis

Pharmaceutical By End Use (USD Billion, 2025-2035)

Research Institutions
Pharmaceutical Companies
Academic Institutions
Clinical Laboratories

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓